Ciclesonide Market To Surpass US$ 657.6 Million Threshold By 2026 - Coherent Market Insights

SEATTLE - July 28, 2021 - PRLog -- The Global Ciclesonide Market, by Indication (Asthma and Allergic Rhinitis), by Dosage Form (Aerosol and Nasal Spray), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 565.4 million in 2018, and is projected to exhibit a CAGR of 1.9% over the forecast period (2018 – 2026).

Inhaled corticosteroids (ICS) such as ciclesonide are at the cornerstone of treatment in asthma and in chronic obstructive pulmonary disease (COPD). The majority of the asthma patients, are treated with a combination of ICS and short- or long- acting bronchodilators. High efficiency of inhaled corticosteroids in treating asthma and COPD incidences is supporting adoption of ciclesonide in the future.

Launches and approvals of new ciclesonide products in key regions is expected to create a conducive environment for growth of the ciclesonide market over the forecast period. For instance, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol for the treatment of allergic rhinitis and launched it in the U.S. market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2291

In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/ciclesonide-market-2291

Key Takeaways of the Ciclesonide Market:

The global ciclesonide market is expected to exhibit a CAGR of 9% over the forecast period, owing to increasing engagement of key players to gain higher market share by employing organic and in-organic strategies such as new product launch and acquisition and divestment.

Among indication, allergic rhinitis segment accounted for major market share in 2017. According to the data published by Allergy UK, allergic rhinitis is a very common non-infectious rhinitis and in the U.K. it affects 10% and 30% of all adults and as many as 40% of children in 2013. As per the same source, around 57% of adult patients and up to 88% of children with allergy rhinitis have sleep problems, including micro-arousals. Such high prevalence of allergic rhinitis is expected to drastically increase demand for ciclesonide, which is widely used in the treatment of allergy rhinitis.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2291